Companies: 10,795·Total market cap: $144.5T
Kinnate Biopharma Inc.

Kinnate Biopharma Inc.

KNTENASDAQHealthcare
$2.65
$-0.01(-0.38%)
Market Cap$124990960
P/E Ratio
52W High$7.185
52W Low$1.04

Kinnate Biopharma Inc. (KNTE) Revenue

Annual & quarterly revenue history · segment & region breakdown

KNTE · revenue · updated Jun 9, 2026

Core revenue metrics

Kinnate Biopharma Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.

TTM revenue
$0.00B
4-quarter sum · USD
YoY growth
+0.00%
vs FY
Price / sales
mktCap ÷ TTM rev
Revenue per day
Est. TTM ÷ 365
Revenue / employee
$0K
84 employees
FY
FY
5Y CAGR
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · Kinnate Biopharma Inc. SEC filings · GAAPUpdated: 2026-06-09

Revenue trend

· Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
KNTE revenue by year · KNTE revenue history · KNTE annual revenue data

Compare revenue vs peers

Biotechnology

Compare KNTE revenue against listed peers. Click any row to open that company's revenue tab.

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income Kinnate Biopharma Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

Kinnate Biopharma Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from Kinnate Biopharma Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Frequently asked questions

KNTE revenue · 4 questions

KNTE's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.

KNTE revenueKNTE annual revenuewhat is KNTE revenueKNTE TTM revenue

Source: FMP · Kinnate Biopharma Inc. SEC filings · GAAP · Kinnate Biopharma Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026